Opinion
Video
CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment
Author(s):
Panelists discuss key updates from the 2024 American Society of Clinical Oncology Annual Meeting and the European Society for Medical Oncology Congress 2024 regarding treatments for unresectable hepatocellular carcinoma (uHCC), including insights from the CheckMmate 9DW study on the use of nivolumab and ipilimumab, and their implications for sequencing and combination therapies in various lines of treatment.
Video content above is prompted by the following:
Dr Finn to group (iIf time allows): Please briefly comment on key updates in treatments for unresectable hepatocellular carcinoma (HCC) uHCC presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) and the European Society for Medical Oncology in Congress 2024 (ESMO 2024) and discuss how these findings may impact affect the overall treatment landscape.
• Dr Kudo: For the phase 3 Checkmate 9DW – study of nNivolumab +plus Iipilimumab (first-line1L HCC) first presented at Phase 3 Study (ASCO 2024), Pplease touch on the expanded analysis presented during ESMO 2024.
i. How does this impact affect sequencing with immune checkpoint inhibitor (ICI) combinations?
ii. What is the role of another ICI combinationo treatment within the secon2rd, 3rdthird, fourth, and beyond lines4L+?
iii. In Wwhat line of therapy would an additional ICI combination be used?
